FY2025 Earnings Estimate for CRGX Issued By Chardan Capital

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Investment analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of CARGO Therapeutics in a note issued to investors on Monday, March 24th. Chardan Capital analyst G. Livshits expects that the company will post earnings of ($3.59) per share for the year. Chardan Capital has a “Neutral” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for CARGO Therapeutics’ FY2026 earnings at ($3.58) EPS.

Several other analysts have also recently weighed in on CRGX. JPMorgan Chase & Co. cut shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a report on Thursday, January 30th. Piper Sandler lowered shares of CARGO Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $34.00 to $4.00 in a report on Thursday, January 30th. William Blair downgraded shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 30th. Truist Financial cut CARGO Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $32.00 to $7.00 in a research note on Thursday, January 30th. Finally, Jefferies Financial Group cut CARGO Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $3.00 in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $15.00.

CARGO Therapeutics Stock Performance

Shares of CRGX opened at $4.04 on Thursday. CARGO Therapeutics has a 1 year low of $3.00 and a 1 year high of $25.45. The stock has a market capitalization of $186.05 million, a PE ratio of -0.95 and a beta of 1.65. The stock has a 50-day simple moving average of $5.67 and a 200-day simple moving average of $13.77.

Institutional Investors Weigh In On CARGO Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brooklyn Investment Group purchased a new position in shares of CARGO Therapeutics during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC boosted its position in shares of CARGO Therapeutics by 565.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company’s stock valued at $84,000 after purchasing an additional 4,929 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of CARGO Therapeutics in the 4th quarter valued at about $141,000. Invesco Ltd. purchased a new position in CARGO Therapeutics during the 4th quarter worth approximately $165,000. Finally, ProShare Advisors LLC acquired a new position in CARGO Therapeutics during the fourth quarter worth approximately $171,000. 93.16% of the stock is currently owned by institutional investors and hedge funds.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.